This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by REINER, B. J. Articles by BERKOVITZ, G. D. Search for Related Content PubMed PubMed Citation Articles by REINER, B. J. Articles by BERKOVITZ, G. D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Genetics Home Reference Hazardous Substances DB TESTOSTERONE

Serum 3-Androstanediol Glucuronide Measurements in Sexually Mature Women with Congenital Adrenal Hyperplasia during Therapy^*

BARRY J. REINER, PATRICIA A. DONOHOUEf, CLAUDE J. MIGEON and GARY D. BERKOVITZ

Division of Pediatric Endocrinology, Johns Hopkins University School of Medicine Baltimore, Maryland 21205

Address all correspondence and requests for reprints to: Patricia A. Donohoue, M.D., Johns Hopkins University School of Medicine, Pediatric Endocrinology, CMSC 3–110, 600 North Wolfe Street, Baltimore, Maryland 21205.

ABSTRACT. Serum 3-androstanediol glucuronide (3-diol G) measurements may indicate the extent of androgen metabolism and action in target tissues. To test this supposition we measured serum 3-diol G concentrations in 23 women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency, including 13 with the salt-losing and 10 with the simple virilizing form, while they were receiving glucocorticoid and, in some cases, mineralocorticoid therapy. Their mean age was 28.3 yr (range, 17.9–38.7 yr). Twenty-four-hour urinary 17-ketosteroid excretion, plasma androstenedione and testosterone levels, and serum 3-diol G levels were measured during the follicular phase. The values were within or below the normal range in 87%, 78%, 70%, and 91% of the patients, respectively. By contrast, plasma 17-hydroxyprogesterone levels were normal in only 12% of the patients. Serum 3-diol G levels correlated well with 24-h urinary 17-ketosteroid excretion (r = 0.75) and plasma 17-hydroxyprogesterone (r = 0.77), androstenedione (r = 0.84), and testosterone (r = 0.93) levels. The serum 3-diol G levels were not significantly different in the women with the salt-losing form and those with the simple virilizing form. However, they were significantly lower (P < 0.05) in the women with normal menses compared to those with abnormal menses. This finding underscores the validity of serum 3-diol G measurements as indicators of androgen production and metabolism in women. The excellent correlation between the serum 3-diol G levels and standard measures of control indicates that the former measurement may be a useful adjunct in the management of women with congenital adrenal hyperplasia.

^* This work was supported by NIH Research Grant DK-00180 (to C.J.M.) and Training Grant DK-07116 (to C.J.M.). Computational assistance for statistical analysis was provided by CLINFO Systems, supported by NIH Grant RR-00035.

Clinician Scientist of the Johns Hopkins University and a Clinical Associate Physician of the NIH (Grant RR-00052).

Received December 15, 1988.

This article has been cited by other articles:

				E. Diamanti-Kandarakis, G. Tolis, and A. J. Duleba Androgens and Therapeutic Aspects of Antiandrogens in Women Reproductive Sciences, July 1, 1995; 2(4): 577 - 592. [Abstract] [PDF]